ArticleMolecular biology reports2026
Investigation of anticancer effects of Boswellia serrata extract in combination with SN-38 on U373 GBM cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlioblastoma (GBM) is an aggressive brain tumor with limited treatment efficacy due to systemic toxicity and therapeutic resistance. This study aimed to evaluate the combined anticancer effects of SN-38, a potent chemotherapeutic agent, and Boswellia serrata, known for its boswellic acid content with apoptosis-inducing properties, on the U373 GBM cell line.
methodsHuman U373 GBM cells were treated for 24 h with control, SN-38 alone (10 µg/ml), Boswellia serrata alone (10, 25, 50 µg/ml), and their various combinations. Cell viability (MTT), total antioxidant status (TAS), total oxidant status (TOS), pro-apoptotic BAX, anti-apoptotic BCL-2, and STAT3 protein levels were analyzed using ELISA. Statistical significance was set at p < 0.05.
resultsBoth SN-38 and Boswellia serrata significantly reduced U373 cell viability. The most pronounced reduction was observed in the SN-38 + Boswellia serrata 25 µg/ml and 50 µg/ml combinations (p < 0.01). Consistent with decreased viability, TAS levels were reduced, and TOS levels increased, particularly in the SN-38 + Boswellia serrata 50 µg/ml group (p < 0.01). Pro-apoptotic BAX expression increased, while anti-apoptotic BCL-2 expression decreased, with the most significant changes observed in the SN-38 + Boswellia serrata 50 µg/ml group (p < 0.01). STAT3 protein levels also decreased in a dose-dependent manner with the combination treatment (p < 0.01).
conclusionThe combination of Boswellia serrata extract and SN-38 effectively activated apoptotic pathways, increased oxidative stress, and reduced cell viability in U373 GBM cells. These findings suggest that this combination may represent a promising novel strategy for glioblastoma treatment.
Indexed as
Identifiers
42423823What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.